Adult Immunization

Anaphylaxis

Food Allergies

Seasonal Allergies

Allergy

Atrial Fibrillation

Heart Failure

Hypertension

Lipid disorders

Cardiology

Clinical Technology

Atopic Dermatitis

Psoriasis

Rosacea

Dermatology

Adrenal Disorders

Diabetes

Thyroid Disorders 

Endocrinology 

C Difficile Infection

Celiac disease

GERD

Inflammatory Bowel Disease

Irritable Bowel Syndrome 

Gastroenterology

Hepatitis

MASLD/MASH

Hepatology

Coronavirus

HIV AIDS

Hepatitis C

Influenza

Pneumonia

Sexually transmitted infections

Infectious Disease

Chronic Kidney Disease

Nephrology

Alzheimer Disease/Dementia

Cerebrovascular Diseases

Epilepsy

Headache

Mental Health

Migraine

Parkinson Disease

Sleep Disorders

Neurology

Obesity Medicine

Fibromyalgia

Pain Management

Pediatric Immunization

Pediatrics

ADHD

Anxiety

Depression

Eating Disorders

PTSD

Panic Disorder  

Psychosis

Substance-related Disorders

Psychiatry 

Asthma

COPD

Cystic Fibrosis

Interstitial lung disease

Pulmonary hypertension

Pulmonology

Gout

Lupus

Osteoarthritis

Psoriatic arthritis

Rheumatoid Arthritis

Rheumatology

Breast Cancer

Cervical Cancer

Colorectal Cancer

Lung Cancer

Melanoma

Prostate Cancer

Renal Cancer

Skin cancer

Screening

Menopause

Osteoporosis

Pregnancy and Birth

Women's Health

News

All News

Editorial Podcasts

Practice Management

Video Interviews

Media

Around the Practice

Between the Lines

ConsultantLive

Frontline Insights

Institutional Insights

Primary View

Provider Toolkits

Screening Series

Conferences

Conference Coverage

Conference Listing

Product Theater Recaps

Resources

Interactive Posters

Product Profile

Publications

Subscribe

CE/CME

Patient Care Online offers clinical news and resources for primary care clinicians, focusing on disease states, guidelines, and trends to improve care.

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online – Primary Care News and Clinical Resources

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

Atopic Dermatitis Provider Toolkit

Adult Immunization Provider Toolkit

Dermatology Hot Topics

1rem

Authors

"Seemingly insignificant impacts on a patient can really change the trajectory of their life so it's very important to treat [atopic dermatitis] early."

Why is Early Treatment of Atopic Dermatitis So Important? Mona Shahriari, MD, Says it Could Change a Life

 Revolutionizing Atopic Dermatitis (RAD) 2025 

meeting in Nashville this month, Mona Shahriari, MD, assistant clinical professor of 

 at the Yale University School of Medicine, gave a presentation titled, "The Psychosocial Impact of Atopic Dermatitis" that focused on the cumulative life course impairment associated with the disease. During an interview at the meeting, 

 asked Shahriari what she hoped might be different in understanding of the emotional 

 if she made the same presentation at RAD 2026. 

"One moment during the session really struck me. I asked the audience how many were familiar with the term cumulative life course impairment. Only 3 or 4 hands went up. That was eye-opening," she said. Her hope for what might be different about this talk next year reflects what she hopes dermatologists at this year's meeting took home with them: 

When a patient with AD walks into your clinic, it might feel like just another rash on the schedule. But for them, it could be the reason they don’t leave the house. It could be the reason they don’t fall in love. It could be the reason they stop dreaming. Taking the time to ask the right questions, to understand the full burden of disease, and to start effective treatment—those things can genuinely transform lives.

Shahriari said she hopes that the research in the area of cumulative life course impairment in AD will have progressed and awareness increased so that when she asks the same question next year, there will be just 3 or 4 hands that do not go up. 

Mona Shahriari, MD is an assistant clinical professor of dermatology at Yale University School of Medicine in New Haven, CT and co-founder of Central Connecticut Dermatology in Cromwell, CT. 

For more RAD 2025 meeting coverage, please click here.

Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.

Clinical Topics

Toolkits

Why Is Early Treatment of Atopic Dermatitis So Important? Mona Shahriari, MD, Says It Could Change a Life

The mother of a 10-year-old boy brings him in for evaluation of his moles (which are all benign). During the visit, the mother asks about the lesions on the first 2 knuckles of his right hand; she initially noticed them several months earlier. The boy is otherwise healthy.

White Knuckles

When We Say "OX40 Inhibition," What Do We Mean? Emma Guttman-Yassky Explains

When We Say "OX40 Inhibition," What Do We Mean? Emma Guttman-Yassky, MD, PhD, Explains

"What does it mean to target OX40 and the OX40 ligand pathway?" Emma Guttman-Yassky, MD, PhD, phrased the question like the veteran dermatology professor and researcher that she is, during a recent interview with 

Guttman-Yassky was in Paris for the 2025 European Academy of Dermatology and Venerology Annual Meeting, held September 17-20. She and colleagues were presenting recent data on the OX40 inhibitor rocatinlimab for the treatment of atopic dermatitis from the phase 3 ROCKET clinical trial program, under the auspices of rocatinlimab codevelopers, Amgen and Kyowa Kirin.

The therapeutic landscape for moderate-to-severe AD has evolved rapidly and significantly in the last decade as targeted therapies have been successively approved and marketed. They include dupilumab (IL-4 receptor antagonist), IL-13 inhibitors (tralokinumab, lebrikizumab), and JAK inhibitors (upadacitinib, abrocitinib, baricitinib).

 These agents have become guideline-recommended first-line systemic treatments, providing superior efficacy and safety compared to conventional immunosuppressants.

There is still a significant unmet need, however, for treatments that can deliver sustained remission and potentially modify the atopic dermatitis disease course. The majority of treatments typically reach maximum efficacy by 12-16 weeks with disease returning quickly when they are stopped. This fact has helped illuminate research into the persistence of underlying immunological memory that drives AD pathogenesis.

This has led to investigation of the OX40-OX40L costimulatory pathway as a novel therapeutic target. As Guttman-Yassky explains in the short video above, OX40 (CD134) is a member of the tumor necrosis factor receptor superfamily expressed on activated T cells, particularly memory T cells, while OX40L (CD252) is expressed on antigen-presenting cells and other immune cells.

The OX40-OX40L interaction provides critical costimulatory signals that promote T-cell activation, proliferation, and survival, with particular importance in maintaining memory T-cell responses.

 In people with atopic dermatitis, this pathway is dysregulated, and elevated expression has been observed in skin lesions and in peripheral blood.

The therapeutic mechanism underlying OX40-OX40L inhibitors is fundamentally  different compared to the current novel biologic therapies, Guttman-Yassky said. It doesn't block downstream cytokine effects or intracellular signaling cascades. The inhibitory mechanism targets upstream costimulatory signals required for T-cell activation and memory formation.

This mechanism potentially offers disease-modifying capabilities through effects on immunological memory—the cellular basis for disease persistence and recurrence at consistent anatomical sites.

Two strategies are being investigated: OX40 receptor antagonism (rocatinlimab, telazorlimab) and OX40L inhibition (amlitelimab). Phase 2 trials have demonstrated promising efficacy with suggestions of continued improvement over extended periods and potential for sustained responses after treatment cessation—characteristics that distinguish these agents from current therapies.

 The following discussion explores the mechanistic rationale for OX40 inhibition and its potential to transform AD management from chronic disease control toward disease modification.

The following transcript has been lightly edited for style and flow. 

Would you explain the mechanism of OX40 inhibition?

What is this pathway? Right? What does it mean to target the OX40ligand pathway? So, the way I like to think about it in a simplistic way, OX40 is a receptor on memory cells, memory T cells, and these are the cells that have the memory a of the disease. So usually when we apply a topical or we take some systemic medications, when we stop the treatment, the disease is coming back. And typically, it's coming back to the same location. Why is that? Because of these memory cells. So, targeting this pathway, what should we expect? We should expect that maybe when we stop the drug, there will be longevity of response. So, it's that idea of disease modification. Now it's possible that the responses will be a little bit slower because we target it a little bit indirectly, but there will be a lot of benefit, because eventually it may have some benefit of disease modification, and that hint of disease modification was seen in phase 2. And while I'm very impressed with the results of this phase 3 study, both the monotherapy and the one with topical steroids, and this is very important, we see still the slope a of the improvement going up at week 24 so this class of drugs will not be judged by week 24, I think a unlike the dupilumab and the IL-13 antagonist, that usually at week 16 they reach the maximal efficacy. This does not reach maximum efficacy at week 24. I bet this will happen at 36 weeks or 48 weeks. You know, I think this drug may need a little bit extra time for the maximum efficacy, but once you reach the efficacy, I think there will be maintenance of response that I'm sure we'll be able to appreciate from the study design. So I'm very excited about this class of drugs and what they are bringing.

Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. 

Davis DMR, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. 

Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. 

Müller S, et al. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Croft M, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. 

Bullock K, Richmond P, McCann L. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. 

Zhai Y, Su J. OX40 in the pathogenesis of atopic dermatitis—a new therapeutic target. 

Guttman-Yassky E, et al. Anti-OX40 biological therapies in the treatment of atopic dermatitis: a comprehensive review. 

Silverberg JI, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. 

Nakagawa H, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. 

EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification. 

Continuous Glucose Monitoring

Older age and lower aerobic fitness are independent risk factors for irregular heartbeats, or 

, in otherwise healthy adults, according to research presented at the European Society of Cardiology (ESC) Congress in Madrid. The findings suggest that arrhythmias, once thought to be benign, may indicate increased risk for future 

The study included 1151 participants aged 40 to 65 years (mean age 52; 88% men) without symptoms of heart disease or structural abnormalities. Participants underwent 

 stress testing with continuous electrocardiography (Holter monitoring) to detect abnormal heart rhythms.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.

Grace Halsey

Articles

Latest Updated Articles